The purpose of the clinical investigation is to support the use of direct procurement of donor hearts in donation after circulatory death followed by hypothermic oxygenated perfusion using the XVIVO Heart Assist Transport System. Thereby increasing the utilization of DCD donor hearts in donation after circulatory death. The primary objective is to evaluate patient survival after direct procurement and hypothermic oxygenated machine perfusion of DCD donor hearts using the XVIVO Heart Assist Transport System. The secondary objectives are to evaluate patient outcomes and graft function post-transplant.
This is a prospective, single-arm, multi-national, multicentre, proof-of-concept study to evaluate post-transplant outcomes after the use of direct procurement followed by a period of hypothermic oxygenated perfusion of the donor heart in DCD using the XVIVO Heart Assist Transport system. The investigation will be conducted at 4 heart transplant centres, one in Belgium and three in The Netherlands.The study will include 40 DCD heart transplant recipients and will evaluate transplant outcomes such as post-transplant complications, patient survival and graft function for a period of 6 months post-transplant. The study will not include a control group as this is a proof-of-concept study, investigating an alternative method of procurement of DCD hearts by providing additional safety and performance data. The primary objective is to evaluate patient survival after direct procurement and hypothermic oxygenated machine perfusion of DCD donor hearts using the XVIVO Heart Assist Transport System. The secondary objectives are to evaluate patient outcomes and graft function post-transplant.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Direct procurement of donor hearts from DCD donation
UZ Leuven
Leuven, Belgium
Patient survival
Time frame: 30 days post-transplant
Cardiac related mortality
Time frame: 30 days post-transplant
Incidence of Mechanical circulatory support
Time frame: 30 days post-transplant
Incidence of severe Primary Graft Dysfunction (PGD) at 24 hours post-transplant (Kobashigawa et al., 2014)
Time frame: 30 days post-transplant
Cardiac function as assessed by left ventricular ejection fraction (LVEF) at 24 hours and 30 days post-transplant
Time frame: 30 days post-transplant
Incidence of perfused hearts which are not used for transplantation
Time frame: 30 days post-transplant
Total duration of ICU stay (days)
Time frame: 30 days post-transplant
Incidence of biopsy proven rejections > 1 ACR (leading to changed immunosuppressive regime)
Time frame: 30 days post-transplant
Cardiac related mortality at 6 months post-transplant
Time frame: 6 months post-transplant
Cardiac function as assessed by left ventricular ejection fraction (LVEF)
Time frame: 6 months post-transplant
Number of days until hospital discharge from index procedure
Time frame: 30 days post-transplant
Incidence of biopsy proven rejections > 1 ACR (leading to changed immunosuppressive regime)
Time frame: 6 months post-transplant
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.